Overview

Phase 1 Study of Oral TP-1454

Status:
Recruiting

Trial end date:
2022-12-01

Target enrollment:

Participant gender:

Summary

This study will evaluate the safety and tolerability of oral TP-1454 in patients with advanced metastatic or progressive solid tumors, alone and in combination with Ipilimumab and Nivolumab.

Phase:

Phase 1

Details

Lead Sponsor:

Sumitomo Dainippon Pharma Oncology, Inc
Tolero Pharmaceuticals, Inc.

Treatments:

Ipilimumab
Nivolumab